Stock Screener App

Frei -

Installieren

1.82

0.55% -0.01

Engene Therapeutics Inc (ENGN)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten

Deep Track Capital Exits enGene Therapeutics (ENGN) Stake in Sec - GuruFocus

enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView

enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat

Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan

enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan

Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan

Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat

Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan

enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com

enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder CancerSlideshow (NASDAQ:ENGN) 2026-08-11 - Seeking Alpha

enGene Therapeutics Inc.Common Stock (ENGN) Stock Price, News, Quote & History - FinancialContent

enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

enGene Therapeutics Inc. (S0N0.F) Latest Press Releases & Corporate News - Yahoo! Finance Canada

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Business Wire

enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat

enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView

enGene (NASDAQ:ENGN) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat

enGene Therapeutics Inc. Revenue Breakdown – NASDAQ:ENGN - TradingView

Siren L.L.C. Has $35.77 Million Stake in enGene Holdings Inc. $ENGN - MarketBeat

Executive options at enGene Therapeutics (ENGN) vesting over 4 years - Stock Titan

enGene Therapeutics (NASDAQ: ENGN) outlines insider RSUs and options - Stock Titan

enGene Therapeutics (ENGN) sees 5.0% beneficial stake reported by Acorn group - Stock Titan

enGene Holdings appoints new chairman to guide growth - The Globe and Mail

enGene Highlights Progress of Lead Bladder Cancer Therapy - TipRanks

enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study - Stock Titan

EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN

enGene Therapeutics announces board changes - The Pharma Letter

enGene names Michael Heffernan board chairman as Richard Glickman steps down - Bitget

enGene Updates Corporate Presentation, Says Pivotal LEGEND 12‑Month Data and BLA Filing Expected 2H 2026 - TradingView

enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Australia

enGene appoints Michael Heffernan as board chairman - Investing.com

Dr. Richard Glickman resigns as chairman of enGene Therapeutics - TradingView

enGene Therapeutics (Nasdaq: ENGN) names new chair, plans BLA filing - Stock Titan

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics - The National Law Review

enGene Therapeutics (ENGN) JMP Hematology and Oncology Summit 2024 Summary - Quartr

enGene reports 54% response rate in bladder cancer trial - Investing.com

Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN

enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView

enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView

Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz

Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView

Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace

ENGN Forecast — Price Target — Prediction for 2027 - TradingView

Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGNW - TradingView

A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo

enGene Therapeutics - The Business Journals

Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo

ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus

EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo

enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters